A March Decision That Could Change Protalix BioTherapeutics Outlook

Verdict

Headline takes no side. We score PLX +0.90 — strongly bullish.

Headline says

No call

No rating or direction in the headline

Expected · PLX

+0.90strongly bullish

−1 bearish0bullish +1

More positive than 95% of ticker scores this week

Actual

Scored by the NIS engine · methodology.

• biotech
• PLX
• chmp
• clinical
• drug approval
• drug revenue
• eua approval
• fabry
• fda approval
• milestone payment
• pharma